Retatrutide, a experimental dual activator of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising outcomes in early human studies. Recent research https://crossbookmark.com/story21235773/retatrutide-emerging-studies-and-possible-therapeutic-roles